Bunn P A
Lung Cancer Program, University of Colorado Cancer Center, Denver 80262, USA.
Semin Oncol. 1996 Dec;23(6 Suppl 15):9-15.
Despite marked improvements in the treatment options available for patients with lung cancers, more than 85% of patients ultimately relapse and die of their disease. Among the most auspicious of new agents available to treat lung cancers, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) also has been the most extensively studied. The US experience with this promising new agent is reviewed here. It is concluded that paclitaxel, both as a single agent and in combination therapies, is as active as other available agents in the treatment of stages III and IV small cell and non-small cell lung cancer, whether given as a 24- or a 1- to 3-hour infusion. In combination therapy, paclitaxel/cisplatin has been shown to be superior to etoposide/cisplatin in the treatment of non-small cell lung cancer. Further study is needed to clarify the optimal role of paclitaxel in combination therapy and to define its optimal dose and schedule in therapy for lung cancers.
尽管肺癌患者的治疗选择有了显著改善，但超过85%的患者最终会复发并死于该疾病。在可用于治疗肺癌的最有前景的新药物中，紫杉醇（泰素；百时美施贵宝公司，新泽西州普林斯顿）也是研究最为广泛的。本文回顾了美国使用这种有前景的新药物的经验。得出的结论是，紫杉醇无论是作为单一药物还是联合治疗，在治疗III期和IV期小细胞肺癌和非小细胞肺癌方面，与其他可用药物一样有效，无论是24小时输注还是1至3小时输注。在联合治疗中，紫杉醇/顺铂已被证明在治疗非小细胞肺癌方面优于依托泊苷/顺铂。需要进一步研究以阐明紫杉醇在联合治疗中的最佳作用，并确定其在肺癌治疗中的最佳剂量和给药方案。
